Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.39 |
| ▸ | KDM4A | O75164 | 6/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25355432 | 0.95 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA4ALDH1A1KDM4C | |
| SCHEMBL25355433 | 0.95 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA4ALDH1A1KDM4C | |
| SCHEMBL21837505 | 0.87 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA4ALDH1A1NOD1 | |
| SCHEMBL21837502 | 0.87 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA4ALDH1A1NOD1 | |
| SCHEMBL31642013 | 0.81 | FOLH1 (0.47) | ALDH1A1NOD1FOLH1 | |
| SCHEMBL31370120 | 0.81 | FOLH1 (0.47) | ALDH1A1NOD1FOLH1 | |
| SCHEMBL1976647 | 0.79 | FFAR4 (0.48) | ALDH1A1FOLH1 | |
| SCHEMBL20732425 | 0.78 | KDM4A (0.40) | ALDH1A1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL805213 | 0.78 | KDM4A (0.40) | ALDH1A1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL1082586 | 0.76 | NOD1 (0.43) | ALDH1A1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | CHRNB2 4641/4885CHRNB4 4733/4885CHRNA4 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.